ClinicalTrials.gg
CompletedNCT04156191Updated Jul 24, 2023

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

A Phase 1 interventional study of ARQ-151 cream 0.15% and ARQ-151 cream 0.05% in Atopic Dermatitis (Eczema), sponsored by Arcutis Biotherapeutics, Inc.. Completed at 10 sites in United States. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Enrollment
8th of 13
101 · median 136
Started
2019
with 1 other
Phase 1
Only one
of the 13
Registered
3rd of 13
by date
Lead sponsor
8 of 13
Arcutis Biotherapeutics, Inc.

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a research study where all subjects will receive study medication to understand how the body processes the study medication, and to determine the PK, safety and efficacy of ARQ-151 cream 0.15% or 0.05% in adolescent and pediatric subjects with mild to moderate AD. At entry, subjects in Cohorts 1-3 will have 1.5-35% Body Surface Area involvement (excluding the scalp, palms, soles) and mild or moderate atopic dermatitis (AD) based on vIGA-AD. Cohort 2 and Cohort 3 will be performed in parallel and may commence after results are available from ARQ-151-212, a Phase 2 study evaluating ARQ-151 cream 0.05% and 0.15% administered once a day for 4 weeks in adolescents and adults with mild to moderate AD affecting 1.5% to 35% BSA.

For the maximal usage PK study (Cohorts 4-8), subjects will have BSA involvement (excluding the scalp, palms, soles) of ≥ 35% in subjects 3 months old to 11 years old (inclusive) or ≥25% in subjects 12 to \<17 years old with mild or moderate AD .

Seven groups will be evaluated, including:

  • Cohort 1: ARQ-151 cream 0.15% in adolescents (12-17 years old; inclusive)
  • Cohort 2: ARQ-151 cream 0.15% in children 6-11 years old (inclusive)
  • Cohort 3: ARQ-151 cream 0.15% in children 2-5 years old (inclusive; will be performed in parallel with Cohort 2)
  • Cohort 4: ARQ-151 cream 0.15% in adolescents 12 to \<17 years old
  • Cohort 5: ARQ-151 cream 0.15% in children 6-11 years old (inclusive)
  • Cohort 6: ARQ-151 cream 0.15% in children 2-5 years old (inclusive)
  • Cohort 7: ARQ-151 cream 0.05% in children 2-5 years old (inclusive)
  • Cohort 8: ARQ-151 cream 0.05% in children 3 months old to less than 2 years old

Subjects will apply ARQ-151 cream 0.15% or 0.05% once a day for 28 days to all AD affected areas and any newly appearing AD lesions that arise during the study, except on the scalp.

03

Conditions studied

  • Atopic Dermatitis (Eczema)
04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. of parent(s) or legal guardian, and, if age appropriate, assent by the subject, as required by local laws.
  2. Males or females, 12-17 years old (inclusive; Cohort 1), or 6-11 years old (inclusive; Cohort 2), or 2-5 years old (inclusive; Cohort 3), and in the maximal usage PK study subjects aged 12 to \<17 years old (Cohort 4), 6 to 11 years old (Cohort 5), 2-5 years old (Cohort 6 and Cohort 7), or 3 months to less than 2 years old (Cohort 8).
  3. Clinical diagnosis of active atopic dermatitis for at least 3 months (2 weeks for Cohort 8).
  4. EASI Score ≥5.
  5. vIGA-AD score of 'Mild' ('2') or 'Moderate ('3').
  6. Has AD involvement of 1.5 to 35% BSA (Cohorts 1-3) or ≥25% BSA (Cohorts 4-7), all excluding the scalp, palms, soles; or for Cohort 8 ≥35% BSA excluding the scalp, perioral, and below wrists/ankles .
  7. Females of must have a negative serum pregnancy test at Screening and, if sexually active, agree to use throughout the trial.
  8. In good health as judged by the Investigator, based on medical history, physical examination, and clinical tests.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any serious medical or psychiatric condition or physical examination or test abnormality that would prevent study participation or place the subject at significant risk.
  2. Subjects with unstable AD or any consistent requirement for high potency topical to manage AD signs or symptoms.
  3. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers or inhibitors.
  4. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Visit 2 and during the study.
  5. Subjects who cannot discontinue systemic and/or topical therapies.
  6. Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
  7. Subjects with actively infected AD or any infection that required oral or intravenous administration of antibiotics, antifungal or antiviral agents
  8. Known or suspected:

    1. severe renal insufficiency or moderate to severe hepatic disorders ( B or C)
    2. history of chronic infectious disease (e.g., , , or (HIV))
    3. to component(s) of the product
    4. history of severe depression, suicidal ideation, Baseline/Screening C-SSRS indicative of suicidal ideation, whether lifetime or recent/current
  9. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  10. Subjects (12 to 17 years old, inclusive) with modified PHQ-A score ≥10 at Screening or Baseline visits.
  11. Subjects (6 to 11 years old, inclusive) with a CDI-2 (parent report) raw score >20 at Screening/Baseline
  12. Subjects with a history of a major surgery within 4 weeks prior to Baseline/Visit 1 or subjects who have a major surgery planned during the study.
  13. Subjects with prior exposure to ARQ-151
  14. Subjects 3 to \<12 months old who were premature at birth
  15. Subject is nursing and subject's mother requires high dose systemic steroids
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    ARQ-151 cream 0.15% or 0.05%

    Open-label study of 0.15% or 0.05% active concentration

    Drug: ARQ-151 cream 0.15% · Drug: ARQ-151 cream 0.05%

Interventions

  • ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days

  • ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of roflumilast and its N-oxide metabolite

    Maximum observed plasma concentration of drug in plasma

    Time frame: 4 weeks

  2. Area under the plasma concentration-time curve within a dosing interval (AUC) for roflumilast and its N-oxide metabolite

    The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in plasma.

    Time frame: 4 weeks

  3. Treatment Emergent Adverse Events (TEAE)

    Number of participants with adverse events during treatment will be assessed.

    Time frame: 4 weeks

Secondary outcomes

  1. Eczema Area and Severity Index (EASI) Total Score Change and Percent Change in Total Score

    Change in EASI Total Score at weeks 2 and 4 and percent change from baseline in EASI Total Score at weeks 2 and 4. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.

    Time frame: Baseline, Week 2, and Week 4

  2. Eczema Area and Severity Index Score 100%, 90%, 75%, and 50% Improvement (EASI100, EASI90, EASI75, and EASI50)

    Proportion of patients with a 100%, 90%, 75%, and 50% or greater improvement in Eczema Area and Severity Index (EASI100, EASI90, EASI75, and EASI50) score from baseline to each study visit. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.

    Time frame: Baseline, Week 2, and Week 4

  3. Achievement of a Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) score of 'clear' or 'almost clear' at each study visit, or 'clear' or 'almost clear' with a 2-point improvement from baseline at each study visit

    The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

    Time frame: Baseline, Week 2, Week 4

  4. Change from baseline in vIGA-AD score at each study visit

    The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

    Time frame: Baseline, Week 2, Week 4

  5. Body Surface Area (BSA) Involvement Change

    Change from baseline in BSA involvement at each study visit.

    Time frame: Baseline, Week 2, Week 4

  6. Worse Itch Numerical Rating Score (WI-NRS) Pruritis Score Change

    Change from baseline in WI-NRS pruritus score at each study visit. WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").

    Time frame: Baseline, Week 2, Week 4

  7. WI-NRS Pruritus Score Improvement

    ≥4-point improvement from Baseline in WI-NRS pruritus score at each study visit. WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").

    Time frame: Baseline, Week 2, Week 4

07

Study locations

10 sites
  • Arcutis Clinical Site 07
    Birmingham, Alabama 35244, United States
  • Arcutis Clinical Site 11
    Rancho Santa Margarita, California 92688, United States
  • Arcutis Clinical Site 02
    Coral Gables, Florida 33146, United States
  • Arcutis Clinical Site 05
    Hialeah, Florida 33016, United States
  • Arcutis Clinical Site 13
    Miami, Florida 33137, United States
  • Arcutis Clinical Site 01
    Mount Pleasant, South Carolina 29464, United States
  • Arcutis Clinical Site 06
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 03
    Orem, Utah 84058, United States
  • Arcutis Clinical Site 10
    West Jordan, Utah 84088, United States
  • Arcutis Clinical Site 12
    Spokane, Washington 99202, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2023, 40 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 40 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2019
First posted
Nov 7, 2019
StartActual
Dec 23, 2019
Primary completionActual
May 2, 2023
CompletionActual
May 2, 2023
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04156191
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Dec 23, 2019
Primary completion
May 2, 2023
Completion
May 2, 2023
Last update
Jul 24, 2023

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion